Core Viewpoint - The article highlights the significant activity in the Hong Kong IPO market, particularly on March 30, 2026, when four companies went public simultaneously, reflecting a resurgence in the market and investor interest in technology sectors such as robotics, AI, and semiconductors [4][19]. Group 1: IPO Highlights - On March 30, 2026, four companies—Hua Yan Robotics, De Shi Bio, Han Tian Tian Cheng, and Ji Shi Jiao—were listed on the Hong Kong Stock Exchange, marking a notable event in the IPO landscape [4][7]. - Han Tian Tian Cheng's stock surged by 44% to HKD 110 per share, with a market capitalization of HKD 46.8 billion; Ji Shi Jiao increased by 49.88% with a market cap of approximately HKD 7 billion; De Shi Bio skyrocketed by 121.21% to a market cap of around HKD 20 billion; and Hua Yan Robotics opened at HKD 16.8 per share, valued at about HKD 9 billion [4][8]. Group 2: Company Profiles - Hua Yan Robotics, established in 2017, is the second-largest collaborative robot company in China, holding a 10.3% market share domestically and 3.5% globally as of 2024. The company uniquely sells both complete robots and core components, creating a competitive edge [8][11]. - Han Tian Tian Cheng is a leading global supplier of silicon carbide epitaxial wafers, with over 30% market share in 2024. The company shifted its IPO plans from the STAR Market to Hong Kong, reducing its fundraising target by over 50% [9][10]. - Ji Shi Jiao has developed an "AI visual algorithm mall" platform, showcasing 1,517 algorithms across various industries, with a project delivery rate exceeding 80% since its inception [10][11]. - De Shi Bio, recognized as the first stock focused on medical imaging AI, has developed the iMedImage® model, which supports 19 imaging modalities and covers over 90% of clinical scenarios [11][12]. Group 3: Market Trends and Reforms - The Hong Kong IPO market has seen a revival, with 39 new listings in 2026, raising over HKD 100 billion by March 30. This resurgence is attributed to regulatory reforms and improved liquidity [19][21]. - The Hong Kong Stock Exchange is undergoing reforms to enhance its competitiveness, including relaxing financial thresholds for listings and increasing the voting rights cap for different share classes, which benefits tech startups [19][23]. - The successful IPOs of these four companies reflect a broader trend of institutional investment in technology sectors, with significant backing from venture capital and private equity firms [14][15][16].

Core Viewpoint - The article provides an overview of recent IPO activities in the Hong Kong, US, and A-share markets, highlighting key companies such as Yushu Technology, Deshi Biotechnology, and SmartMore Inc. Group 1: Yushu Technology - Yushu Technology's IPO application was accepted on March 20, aiming to raise CNY 4.202 billion [3] - Founded in 2016, Yushu Technology focuses on self-research in general robotics, achieving significant market share in quadruped and humanoid robots, especially overseas [3] - The company sold over 30,000 quadruped robots from 2022 to 2024, establishing a strong position in the global market [3] - Yushu Technology's revenue is projected to reach CNY 1.708 billion in 2025, with a year-on-year growth of 335.36%, and a net profit of CNY 600 million, up 674.29% [4] - Major investors include Meituan, Sequoia China, and Matrix Partners, with Meituan holding 9.65% of shares [4] Group 2: Deshi Biotechnology - Deshi Biotechnology commenced its IPO process on March 19, with plans to list on the Hong Kong Stock Exchange under the code "2526" [6] - The company aims to raise up to HKD 900 million through the issuance of 7,999,200 shares, with a market valuation potentially reaching nearly HKD 10 billion [6] - Deshi Biotechnology specializes in medical imaging products, with its core product, AI AutoVision®, designed for chromosome karyotype analysis, already completing clinical trials [7] - The company holds a 30.6% market share in China's chromosome karyotype analysis sector, leading the market as of 2024 [8] Group 3: SmartMore Inc. - SmartMore Inc. submitted its IPO application to the Hong Kong Stock Exchange on March 16, aiming to become the first "Industrial AI Intelligent Agent" stock [10][11] - The company provides a comprehensive AI technology system for manufacturing, serving over 730 clients globally, including Tesla and BOE [11] - Revenue projections for SmartMore Inc. are CNY 485 million in 2023, CNY 756 million in 2024, and CNY 1.086 billion in 2025, with growth rates of 55.9% and 43.7% respectively [11] - The company has received investments from notable firms, achieving a valuation of USD 1.23 billion before its IPO [12][13]

Group 1 - The core viewpoint of the article highlights the significant increase in southbound capital holdings in Yipai Yangguang (02522.HK), with a total of 98.45 million shares added on February 27 [1] - Over the past five trading days, southbound capital has increased its holdings on two occasions, resulting in a net increase of 244,000 shares [1] - In the last twenty trading days, there have been eleven days of net increases, totaling 3.7915 million shares [1] Group 2 - As of now, southbound capital holds 143 million shares of Yipai Yangguang, accounting for 48.58% of the company's total issued ordinary shares [1] - Yipai Yangguang Group Co., Ltd. primarily engages in specialized medical imaging services in China [1] - The company operates three segments: imaging center services, imaging solutions, and Yipai cloud services, providing diagnostic services, equipment procurement assistance, and data-driven operational support [1]

Core Viewpoint - Southbound funds have significantly increased their holdings in Yipai Sunshine (02522.HK), indicating strong investor interest in the company [1] Group 1: Southbound Fund Activity - On February 10, southbound funds increased their holdings by 265,000 shares in Yipai Sunshine (02522.HK) [1] - Over the past 5 trading days, there have been 4 days of net increases in holdings, totaling 2,194,500 shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 9,660,500 shares [1] - Currently, southbound funds hold 14.3 million shares of Yipai Sunshine, representing 48.49% of the company's issued ordinary shares [1] Group 2: Company Overview - Jiangxi Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China [1] - The company offers medical imaging services and solutions through three main divisions [1] - The Imaging Center Services provide imaging examinations and diagnostic services to patients and healthcare consumers [1] - The Imaging Solutions Services assist hospitals and medical institutions in selecting and procuring suitable imaging equipment, along with providing modular solutions [1] - Yipai Cloud Services support the development of imaging center services, information management, and data-driven operations [1]

Core Viewpoint - Southbound funds reduced their holdings in Yimai Sunshine (02522.HK) by 71,000 shares on February 9, while there were net increases in holdings for 3 out of the last 5 trading days, totaling 1.702 million shares. Over the last 20 trading days, there were net increases for 12 days, amounting to 7.445 million shares [1] Company Overview - Jiangxi Yimai Sunshine Group Co., Ltd. is primarily engaged in specialized medical imaging services in China. The company offers medical imaging services and solutions [1] - The company operates through three segments: Imaging Center Services, Imaging Solutions, and Yimai Cloud Services. Imaging Center Services provide imaging examinations and diagnostic services to patients and healthcare consumers through flagship imaging centers [1] - Imaging Solutions assist hospitals and other medical institutions in selecting and procuring suitable imaging equipment to meet their development needs, along with providing a range of modular solutions [1] - Yimai Cloud Services support the development of imaging center services, information management, and data-driven operations [1]

Core Viewpoint - The insurance industry is transitioning from traditional risk compensation to a comprehensive health management service model, focusing on prevention, intervention, and claims, as exemplified by the strategic partnership between Century Life Insurance Co., Ltd. and Panoramic Medical Imaging Technology Co., Ltd. [1][4] Group 1: Strategic Cooperation - The strategic signing ceremony took place on January 16, 2026, in Shanghai, marking the beginning of a deeper collaboration between the two companies [2] - The partnership aims to integrate advanced medical imaging technology and health screening services into insurance offerings, emphasizing early disease detection and prevention [4] Group 2: Value Reconstruction - The collaboration reflects a shift in health protection philosophy, moving from post-event compensation to proactive prevention and early intervention [4] - Century Life is restructuring its service model to focus on the entire customer lifecycle, integrating prevention, protection, and service [4] Group 3: Health Management Services - Panoramic Medical has over a decade of experience in high-end medical services, focusing on cancer and cardiovascular disease diagnostics, and offers a range of health management services [6] - The partnership combines professional medical services with quality insurance, creating a comprehensive health management and risk protection system [6] Group 4: Industry Benchmarking - The collaboration is seen as a response to the call for technological finance and inclusive finance, aiming to make advanced medical technology accessible to a broader population [8] - The goal is to reduce the burden of major diseases on individuals and society, contributing to the vision of a "Healthy China" and promoting longevity [8] Group 5: Company Overview - Century Life Insurance was established on June 3, 2009, and has expanded to 20 provincial branches and over 370 sub-branches across more than 150 major cities in China [9] - As of December 2024, the company has total assets nearing 280 billion yuan and has paid out over 11.2 billion yuan in claims, providing significant insurance and health services to millions [9]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has disclosed that five companies have recently obtained approval for overseas issuance and listing or full circulation of unlisted shares in China, all targeting the Hong Kong Stock Exchange and are in the process of secondary applications [1] Group 1: Company Summaries - Stone Technology, once known as a "sweeping broom" in the A-share market, saw its stock price peak at 1494.99 yuan per share in June 2021, with a market capitalization of 99.266 billion yuan, but has since decreased to a total market value of 42.361 billion yuan, representing a decline of over 50%. The company plans to issue no more than 33.108 million shares [1] - Haizhi Technology, an AI application company founded by former Baidu executives and backed by Hillhouse Capital, focuses on products like the Atlas mapping solution and Atlas intelligent agents. It intends to issue no more than 47.5846 million shares and convert 372 million shares held by shareholders into H-shares [1] - Yushi Technology specializes in L4-level autonomous driving technology, with investors including Innovation Works. The company plans to issue no more than 18.9142 million shares and convert 112 million shares held by shareholders into H-shares [1] - Deshi Biotech aims to become the first company to launch a medical imaging large model, planning to issue no more than 31.004 million shares and convert 80.88 million shares held by shareholders into H-shares [1] - Shangmi Technology, a provider of commercial IoT (BIoT) solutions with shareholders including Ant Group, Meituan, and Xiaomi, plans to issue no more than 46.004 million shares and convert 261 million shares held by shareholders into H-shares [1]

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Yipai Sunshine (02522.HK) by 1.022 million shares on January 8, while experiencing a net reduction of 0.887 million shares over the last five trading days [1] - Over the past 20 trading days, Yipai Sunshine faced net reductions in holdings for 10 days, totaling 3.7445 million shares [1] - Currently, southbound funds hold 13.3 million shares of Yipai Sunshine, representing 45.1% of the company's total issued ordinary shares [1] Group 2 - Yipai Sunshine Group Co., Ltd. is primarily engaged in specialized medical imaging services in China [1] - The company offers medical imaging services and solutions through three main divisions: imaging center services, imaging solutions, and Yipai cloud services [1] - The imaging center services provide diagnostic imaging examinations to patients and healthcare consumers, while imaging solutions assist hospitals in selecting and procuring suitable imaging equipment [1]

Group 1 - The core message of the event is the potential for collaboration between South Korean and Chinese startups, particularly in the fields of artificial intelligence and smart hardware, as emphasized by MiniMax's founder Yan Junjie [1] - The South Korean government, represented by President Yoon Suk-yeol, expressed strong support for fostering exchanges and collaborations between the two countries' entrepreneurial ecosystems [3] - The forum highlighted the significant interest from South Korean startups in entering the Chinese market, with many companies seeking partnerships to leverage China's vast market potential [1][3] Group 2 - LUNIT's CEO Xu Banshi called for the establishment of a Sino-Korean startup group to collaboratively build a data center and conduct data validation work, aiming to identify cooperative projects [2] - CMBI's CEO Huo Jianjun suggested that South Korean companies leverage their semiconductor technology advantages in conjunction with Chinese market applications to create substantial synergies [2] - The event showcased over 50 Korean beauty brands, indicating a strong interest in the Chinese beauty market, with the First Lady of South Korea praising the diversity and responsiveness of these brands to market demands [3]

Core Viewpoint - The China Securities Regulatory Commission has approved the overseas listing of Hangzhou Deshi Biotechnology Co., Ltd., allowing the company to issue up to 31.04 million shares for listing on the Hong Kong Stock Exchange, while 27 shareholders will convert a total of 80.88 million domestic unlisted shares into overseas listed shares [1] Group 1: Company Overview - Deshi Biotechnology is a leading enterprise in the field of medical imaging AI and medical imaging equipment, with a global market presence [1] - The company has developed a diversified product matrix based on its self-developed general medical imaging base model, iMedImage, including systems for chromosome karyotype analysis and automatic cell imaging [1] - In 2024, Deshi Biotechnology achieved a market share of 30.6% in China's chromosome karyotype analysis sector, ranking first and breaking the long-standing monopoly of imported brands [1] Group 2: Market Position and Recognition - The company has established a customer base covering over 400 medical care centers and institutions across China, gaining widespread market recognition [1] - In 2025, Deshi Biotechnology was selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog" due to its technological innovation and clinical value [1] Group 3: Future Plans - The company plans to continue providing standardized intelligent imaging equipment, a Model-as-a-Service (MaaS) cloud platform, and localized self-training solutions to enhance the efficiency, accuracy, and accessibility of medical imaging diagnostics [2] - Deshi Biotechnology aims to lead the global medical imaging industry into an era of intelligence through technological innovation [2]